Dual-target ligand discovery for Alzheimer’s disease: triphenylphosphoranylidene derivatives as inhibitors of acetylcholinesterase and β-amyloid aggregation. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.